All Primary Antibodies
All Primary Antibodies
Primary antibodies, immunoglobulins that bind to specific proteins or other biomolecules, are used in many research applications and protocols to detect targets of interest. They are developed using different animal hosts, including mouse, rat, rabbit, goat, sheep, and many others.
Monoclonal and Polyclonal Antibodies
One type of primary antibodies, monoclonal antibodies, provides high reproducibility and low cross-reactivity and background noise. Another type, polyclonal antibodies, often costs less and provides greater affinity and quicker binding. Both are produced using plasma B cells, but the former uses the same clone and the latter uses different clones. Monoclonal antibodies require hybridoma cell lines, and polyclonal antibodies do not.
There are also recombinant monoclonal antibodies with similar benefits, like high affinity, scalability, and specificity. They are produced using in vitro cloning of plasma B cells and expression hosts.
Conjugated Primary Antibodies
Antibodies can be labeled with various fluorophores or detection agents or used without labels. Labeled primary antibodies, also known as conjugated primary antibodies, help researchers simplify and streamline their applications. They are coupled with common enzymes and dyes such as Alexa Fluor and often used in protein and cell analysis.
Applications
Antibodies for life sciences applications are used in flow cytometry, western blotting, ELISA, immunohistochemistry, and immunocytochemistry. Secondary antibodies can be added to support the detection and purification of certain antigens. They bind to the primary antibody, which binds to the antigen of interest. Finding the right combination of antibodies can result in greater antigen specificity and a strong, detectable signal.
ACROBiosystems ACROBiosystems Anti-Adalimumab Antibodies
Antibody;1MG;IgG1/kappa;Recognizes Adalimumab specifically, no cross reactivity with other humanized antibodies.;Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Adalimumab F(ab')2.; ;Anti-Adalimumab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development.Immobilized adalimumab at 1 µg/mL, add increasing concentrations of Anti-Adalimumab Antibodies (Cat. No. ADB-Y19, 10% human serum) and then add biotinylated adalimumab at 5 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 0.6 ng/mL. ;Demonstration of the specificity of Anti-Adalimumab Antibodies (Cat. No. ADB-Y19) to the adalimumab.;Anti-Adalimumab Antibodies (mouse IgG1, Cat. No. ADB-Y19) captured on CM5 chip via anti-mouse antibodies surface, can bind human adalimumab with an affinity constant of 1.36 pM.
ACROBiosystems ACROBiosystems Anti-Adalimumab Antibodies
Antibody;100UG;IgG1/kappa;Recognizes Adalimumab specifically, no cross reactivity with other humanized antibodies.;Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Adalimumab F(ab')2.; ;Anti-Adalimumab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development.Immobilized adalimumab at 1 µg/mL, add increasing concentrations of Anti-Adalimumab Antibodies (Cat. No. ADB-Y19, 10% human serum) and then add biotinylated adalimumab at 5 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 0.6 ng/mL. ;Demonstration of the specificity of Anti-Adalimumab Antibodies (Cat. No. ADB-Y19) to the adalimumab.;Anti-Adalimumab Antibodies (mouse IgG1, Cat. No. ADB-Y19) captured on CM5 chip via anti-mouse antibodies surface, can bind human adalimumab with an affinity constant of 1.36 pM.
ACROBiosystems ACROBiosystems Anti-Cetuximab Antibodies
Antibody;1MG;IgG1/kappa;Recognizes Cetuximab specifically, no cross reactivity with other humanized antibodies.;Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Cetuximab F(ab')2.; ;Anti-Cetuximab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development. Immobilized cetuximab at 1 µg/mL, add increasing concentrations of Anti-Cetuximab Antibodies (Cat. No. CEB-Y28, 10% human serum) and then add biotinylated cetuximab at 5 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 2.4 ng/mL. ;Demonstration of the specificity of Anti-Cetuximab Antibodies (Cat. No. CEB-Y28) to the cetuximab.;Anti-Cetuximab Antibodies (mouse IgG1, Cat. No. CEB-Y28) captured on CM5 chip via anti-mouse antibodies surface, can bind Human cetuximab with an affinity constant of 1.51 pM.
ACROBiosystems ACROBiosystems Anti-Cetuximab Antibodies
Antibody;100UG;IgG1/kappa;Recognizes Cetuximab specifically, no cross reactivity with other humanized antibodies.;Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Cetuximab F(ab')2.; ;Anti-Cetuximab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development. Immobilized cetuximab at 1 µg/mL, add increasing concentrations of Anti-Cetuximab Antibodies (Cat. No. CEB-Y28, 10% human serum) and then add biotinylated cetuximab at 5 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 2.4 ng/mL. ;Demonstration of the specificity of Anti-Cetuximab Antibodies (Cat. No. CEB-Y28) to the cetuximab.;Anti-Cetuximab Antibodies (mouse IgG1, Cat. No. CEB-Y28) captured on CM5 chip via anti-mouse antibodies surface, can bind Human cetuximab with an affinity constant of 1.51 pM.
ACROBiosystems ACROBiosystems Anti-Rituximab Antibodies (MALS verified)
Antibody;100UG;IgG1 / kappa;Recognizes Rituximab specifically, no cross reactivity with other humanized antibodies.;Anti-Rituximab Antibodies (RIB-Y35c) are expressed from human 293 cells (HEK293).;This protein . ;Immobilized Rituximab at 1 μg/mL (100 μL/well) can bind Anti-Rituximab Antibodies (Cat. No. RIB-Y35c) with a linear range of 0.2-6 ng/mL (QC tested).
ACROBiosystems ACROBiosystems Human CD47-coupled Magnetic Beads
Beads;2MG;The magnetic beads technology makes use of the easy and efficient collection of beads in magnetic field to facilitate antibody purification in a simple workflow of “bind-wash-elute”. In contrast to common separation techniques, this method does not require columns or centrifugation, and is therefore ideal in high-throughput applications.
ACROBiosystems ACROBiosystems Human CD47-coupled Magnetic Beads
Beads;10MG;The magnetic beads technology makes use of the easy and efficient collection of beads in magnetic field to facilitate antibody purification in a simple workflow of “bind-wash-elute”. In contrast to common separation techniques, this method does not require columns or centrifugation, and is therefore ideal in high-throughput applications.
ACROBiosystems ACROBiosystems Anti-Cetuximab Antibodies (Non-Neutralizing)
Antibody;1MG;IgG1/kappa;Recognizes Cetuximab specifically, no cross reactivity with other humanized antibodies.;Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Cetuximab F(ab')2.; ;Anti-Cetuximab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development.Immobilized cetuximab at 1 µg/mL, add increasing concentrations of Anti-Cetuximab Antibodies (Cat. No. CEB-Y31, 10% human serum) and then add biotinylated cetuximab at 2 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 39 ng/mL. ;Demonstration of the specificity of Anti-Cetuximab Antibodies (Cat. No. CEB-Y31) to the cetuximab.;Anti-Cetuximab Antibodies (mouse IgG1, Cat. No. CEB-Y31) captured on CM5 chip via anti-mouse antibodies surface, can bind human cetuximab with an affinity constant of 0.421 nM.
ACROBiosystems ACROBiosystems Human ANGPT2-coupled Magnetic Beads
Beads;10MG;The magnetic beads technology makes use of the easy and efficient collection of beads in magnetic field to facilitate antibody purification in a simple workflow of “bind-wash-elute”. In contrast to common separation techniques, this method does not require columns or centrifugation, and is therefore ideal in high-throughput applications. ;Immobilized 47μg ANGPT2 protein/1mg beads can bind Human TIE2 Protein, Fc Tag (Cat.No. TI2-H5255) with an EC50 of 3.228 μg/mL (QC tested).
ACROBiosystems ACROBiosystems Human CD73-coupled Magnetic Beads
Beads;10MG;The magnetic beads technology makes use of the easy and efficient collection of beads in magnetic field to facilitate antibody purification in a simple workflow of “bind-wash-elute”. In contrast to common separation techniques, this method does not require columns or centrifugation, and is therefore ideal in high-throughput applications. ;Immobilized 62 μg CD73 protein to 1 mg Beads can bind the Anti-CD73 Antibody with an EC50 of 0.5659 μg/mL (QC tested).
ACROBiosystems ACROBiosystems Anti-Rituximab Antibodies (MALS verified)
Antibody;1MG;IgG1 / kappa;Recognizes Rituximab specifically, no cross reactivity with other humanized antibodies.;Anti-Rituximab Antibodies (RIB-Y35c) are expressed from human 293 cells (HEK293).;This protein . ;Immobilized Rituximab at 1 μg/mL (100 μL/well) can bind Anti-Rituximab Antibodies (Cat. No. RIB-Y35c) with a linear range of 0.2-6 ng/mL (QC tested).
ACROBiosystems ACROBiosystems Human EGFRvIII-coupled Magnetic Beads
Beads;2MG;The magnetic beads technology makes use of the easy and efficient collection of beads in magnetic field to facilitate antibody purification in a simple workflow of “bind-wash-elute”. In contrast to common separation techniques, this method does not require columns or centrifugation, and is therefore ideal in high-throughput applications. ;Immobilized 44 μg EGFRvIII protein/1 mg beads can bind Anti-EGFR Antibody (Cetuximab) with an EC50 of 0.7172 μg/mL (QC tested).;Immobilized 44 μg EGFRvIII protein/1mg beads can bind Anti-EGFRvIII Antibody with an EC50 of 0.8856 μg/mL (QC tested).
ACROBiosystems ACROBiosystems Human EGFRvIII-coupled Magnetic Beads
Beads;10MG;The magnetic beads technology makes use of the easy and efficient collection of beads in magnetic field to facilitate antibody purification in a simple workflow of “bind-wash-elute”. In contrast to common separation techniques, this method does not require columns or centrifugation, and is therefore ideal in high-throughput applications. ;Immobilized 44 μg EGFRvIII protein/1 mg beads can bind Anti-EGFR Antibody (Cetuximab) with an EC50 of 0.7172 μg/mL (QC tested).;Immobilized 44 μg EGFRvIII protein/1mg beads can bind Anti-EGFRvIII Antibody with an EC50 of 0.8856 μg/mL (QC tested).
ACROBiosystems ACROBiosystems Human CD73-coupled Magnetic Beads
Beads;2MG;The magnetic beads technology makes use of the easy and efficient collection of beads in magnetic field to facilitate antibody purification in a simple workflow of “bind-wash-elute”. In contrast to common separation techniques, this method does not require columns or centrifugation, and is therefore ideal in high-throughput applications. ;Immobilized 62 μg CD73 protein to 1 mg Beads can bind the Anti-CD73 Antibody with an EC50 of 0.5659 μg/mL (QC tested).
ACROBiosystems ACROBiosystems Anti-Cetuximab Antibodies (Non-Neutralizing)
Antibody;100UG;IgG1/kappa;Recognizes Cetuximab specifically, no cross reactivity with other humanized antibodies.;Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Cetuximab F(ab')2.; ;Anti-Cetuximab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development.Immobilized cetuximab at 1 µg/mL, add increasing concentrations of Anti-Cetuximab Antibodies (Cat. No. CEB-Y31, 10% human serum) and then add biotinylated cetuximab at 2 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 39 ng/mL. ;Demonstration of the specificity of Anti-Cetuximab Antibodies (Cat. No. CEB-Y31) to the cetuximab.;Anti-Cetuximab Antibodies (mouse IgG1, Cat. No. CEB-Y31) captured on CM5 chip via anti-mouse antibodies surface, can bind human cetuximab with an affinity constant of 0.421 nM.